Evidence map›Paper›PMID 40156032›Full record

ArticleTrials2025

Cognitive Level Enhancement through Vision Exams and Refraction (CLEVER): study protocol for a randomised controlled trial.

Srinivas Marmamula, Suvarna Alladi, Keerthana Umapathy, Ving Fai Chan, Graeme MacKenzie, Lynne Lohfeld, Asha Latha Mettla, Sridevi Rayasam, Vijaya K Gothwal, Raja Narayanan and 25 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05458323 (Cognitive Level Enhancement Through Vision Exams and Refraction), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05458323 narecruitingnot on this map

Cognitive Level Enhancement Through Vision Exams and Refraction: a Randomized Controlled Trial to Assess Impact of Near and Distance Spectacles on Reducing Rates of Cognitive Decline With Aging in Community Dwelling Older People in India

TypeinterventionalSponsorQueen's University, BelfastRan2024 to 2028Enrolled820ConditionsRefractive ErrorsArmsFree near and Distance Vision glasses
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. [Vision loss, cognitive decline and dementia-A narrative review article].Zeitschrift fur Gerontologie und Geriatrie · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Srinivas Marmamula *Allen Foster Community Eye Health Research Centre, Gullapalli Pratibha Rao International Centre for Advancement of Rural Eye Care, L V Prasad Eye Institute, Hyderabad, India.
Suvarna Alladi *National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India.
Keerthana UmapathyNational Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India.
Ving Fai ChanCentre for Public Health, Queen's University Belfast (QUB), Belfast, UK.
Graeme MacKenzieRiemann Limited, London, UK.
Lynne LohfeldCentre for Public Health, Queen's University Belfast (QUB), Belfast, UK.
Asha Latha MettlaAllen Foster Community Eye Health Research Centre, Gullapalli Pratibha Rao International Centre for Advancement of Rural Eye Care, L V Prasad Eye Institute, Hyderabad, India.
Sridevi RayasamClinical Trials Unit, L V Prasad Eye Institute, Hyderabad, India.
Vijaya K GothwalPatient-Reported Outcomes Unit - Brien Holden Eye Research Centre, L V Prasad Eye Institute, Hyderabad, India.
Raja NarayananClinical Trials Unit, L V Prasad Eye Institute, Hyderabad, India.
Giridhar PydaAllen Foster Community Eye Health Research Centre, Gullapalli Pratibha Rao International Centre for Advancement of Rural Eye Care, L V Prasad Eye Institute, Hyderabad, India.
Harithaa P ChadalavadaAllen Foster Community Eye Health Research Centre, Gullapalli Pratibha Rao International Centre for Advancement of Rural Eye Care, L V Prasad Eye Institute, Hyderabad, India.
Priya ThomasNational Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India.
Lovemore Nyasha SigwadhiClinical Trials Unit, L V Prasad Eye Institute, Hyderabad, India.
Augusto Azuara-BlancoCentre for Public Health, Queen's University Belfast (QUB), Belfast, UK.
Cliona McDowellNorthern Ireland Clinical Trials Unit (NICTU), Queens University Belfast (QUB), Belfast, UK.
Susan McMullanNorthern Ireland Clinical Trials Unit (NICTU), Queens University Belfast (QUB), Belfast, UK.
Lynn MurphyNorthern Ireland Clinical Trials Unit (NICTU), Queens University Belfast (QUB), Belfast, UK.
Mike ClarkeNorthern Ireland Clinical Trials Unit (NICTU), Queens University Belfast (QUB), Belfast, UK.
Joshua R EhrlichInstitute for Social Research, University of Michigan, Ann Arbor, MI, USA.
Bonnielin SweenorJohns Hopkins University, Baltimore, MD, USA.
Ciaran O'NeillSchool of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast (QUB), Belfast, UK.
Shashidhar KomaravoluAlzheimers and Related Disorders Society of India (ARDSI), Hyderabad, India.
Pallab K MaulikGeorge Institute for Global Health, New Delhi, India.
G V S MurthyPRASHO Foundation, Hyderabad, India.
Keshav KumarNational Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India.
Anant NyshadhamUniversity of Michigan, Ann Arbor, MI, USA.
Achyuta AdhvaryuUniversity of Michigan, Ann Arbor, MI, USA.
Christopher McCabeCentre for Public Health, Queen's University Belfast (QUB), Belfast, UK.
David E BloomDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Jinkook LeeUniversity of Southern California, Santa Monica, CA, USA.
Frank LinCochlear Center for Hearing and Public Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MA, USA.
Seán CoghlanSchool of Medicine, Queen's University Belfast (QUB), Belfast, UK.
Rohit C KhannaAllen Foster Community Eye Health Research Centre, Gullapalli Pratibha Rao International Centre for Advancement of Rural Eye Care, L V Prasad Eye Institute, Hyderabad, India. rohit@lvpei.org.
Nathan CongdonCentre for Public Health, Queen's University Belfast (QUB), Belfast, UK. ncongdon1@gmail.com.ORCID http://orcid.org/0000-0001-9866-3416

Funding

Leveraging a natural experiment to estimate the causal impact of blood sugar on dementia and cognition in IndiaR01AG051125 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Jinkook Lee · 2015 to 2026
$26.8M
NIA NIH HHS R01 AG051125Wellcome Trust 222490Wellcome Trust 222490/Z/21/Z
6 · The paper itself

Abstract

backgroundLongitudinal observational studies have found an association between vision impairment and accelerated decline in cognition. However, no randomised trials have assessed the possible benefit of vision correction on cognitive change. We present the protocol for a three-year randomised controlled trial designed to assess the impact of spectacles for distance and/or near vision correction on cognitive change among community-dwelling elderly participants in India.

methodsCognitive Level Enhancement through Vision Exams and Refraction (CLEVER) is a single-centre, open-label, parallel-group, individually-randomised trial. Participants (760 total, 380 in each arm) aged ≥ 60 years with correctable vision impairment at distance and/or near (presenting visual acuity < 6/18 in the better-seeing eye and improving to > = 6/18 with spectacles and/or presenting near vision worse than N6 at 40 cm and improving to N6 with spectacles), normal hearing (able to repeat at least three out of six words whispered from a 50 cm distance in the better ear) and normal cognition (Hindi Mini-mental Status Examination score > 18/31) will be enrolled. After a comprehensive eye examination, intervention group participants will receive distance, near, or bifocal spectacles, while controls will receive a prescription and spectacles at the end of the trial. The primary outcome will be the three-year change in Longitudinal Aging Study in India-Diagnostic Assessment of Dementia (LASI DAD) global cognitive factor score, with and without adjustment for baseline score, age, gender, education and other potential confounders.

conclusionCLEVER is designed to assess the effectiveness of spectacles as a low-cost intervention to prevent or delay cognitive decline.

trial registrationThis trial is registered with ClinicalTrials.gov, number NCT05458323, February 15, 2023.

Indexed as

CognitionCognitive AgingEyeglassesRefraction, OcularVision DisordersVision TestsAgedFemaleHumansIndiaMaleMiddle AgedRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeVisual AcuityCognitive declineCorrectable vision lossDementiaElderlyIndiaLASI-DADRandomised controlled trial

Identifiers

PMID40156032
PMCPMC11954208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.